Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Motor phenotype classification in moderate to advanced PD in BioFIND study.

Luo L, Andrews H, Alcalay RN, Poyraz FC, Boehme AK, Goldman JG, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Sutherland M, Kopil C, Naito A, Kang UJ.

Parkinsonism Relat Disord. 2019 Jun 23. pii: S1353-8020(19)30280-9. doi: 10.1016/j.parkreldis.2019.06.017. [Epub ahead of print]

PMID:
31255537
2.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
3.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

PMID:
30111645
4.

Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4).

Beach TG, Serrano GE, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé AG, Letournel F, Munoz DG, White CL 3rd, Schneider J, Crary JF, Sue LI, Adler CH, Glass MJ, Intorcia AJ, Walker JE, Foroud T, Coffey CS, Ecklund D, Riss H, Goßmann J, König F, Kopil CM, Arnedo V, Riley L, Linder C, Dave KD, Jennings D, Seibyl J, Mollenhauer B, Chahine L; Systemic Synuclein Sampling Study (S4) .

J Neuropathol Exp Neurol. 2018 Sep 1;77(9):793-802. doi: 10.1093/jnen/nly056.

PMID:
30107604
5.

Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.

Berk S, Greco BL, Biglan K, Kopil CM, Holloway RG, Meunier C, Simuni T.

J Parkinsons Dis. 2017;7(4):685-693. doi: 10.3233/JPD-171199.

6.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

7.

The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.

Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D; Systemic Synuclein Sampling Study (S4).

Biomark Med. 2017 Apr;11(4):359-368. doi: 10.2217/bmm-2016-0366. Epub 2017 Mar 29.

8.

Primary blast injury causes cognitive impairments and hippocampal circuit alterations.

Beamer M, Tummala SR, Gullotti D, Kopil C, Gorka S, Ted Abel, Bass CR, Morrison B 3rd, Cohen AS, Meaney DF.

Exp Neurol. 2016 Sep;283(Pt A):16-28. doi: 10.1016/j.expneurol.2016.05.025. Epub 2016 May 28.

9.

The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.

Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Rudolph A, Casaceli C, Andrews H, Gwinn K, Sutherland M, Kopil C, Vincent L, Frasier M.

Mov Disord. 2016 Jun;31(6):924-32. doi: 10.1002/mds.26613. Epub 2016 Apr 26.

10.

Calpain-cleaved type 1 inositol 1,4,5-trisphosphate receptor impairs ER Ca(2+) buffering and causes neurodegeneration in primary cortical neurons.

Kopil CM, Siebert AP, Foskett JK, Neumar RW.

J Neurochem. 2012 Oct;123(1):147-58. doi: 10.1111/j.1471-4159.2012.07859.x. Epub 2012 Aug 14.

11.

Calpain-cleaved type 1 inositol 1,4,5-trisphosphate receptor (InsP(3)R1) has InsP(3)-independent gating and disrupts intracellular Ca(2+) homeostasis.

Kopil CM, Vais H, Cheung KH, Siebert AP, Mak DO, Foskett JK, Neumar RW.

J Biol Chem. 2011 Oct 14;286(41):35998-6010. doi: 10.1074/jbc.M111.254177. Epub 2011 Aug 22.

12.

Impact of therapeutic hypothermia onset and duration on survival, neurologic function, and neurodegeneration after cardiac arrest.

Che D, Li L, Kopil CM, Liu Z, Guo W, Neumar RW.

Crit Care Med. 2011 Jun;39(6):1423-30. doi: 10.1097/CCM.0b013e318212020a.

13.

RNAi targeting micro-calpain increases neuron survival and preserves hippocampal function after global brain ischemia.

Bevers MB, Ingleton LP, Che D, Cole JT, Li L, Da T, Kopil CM, Cohen AS, Neumar RW.

Exp Neurol. 2010 Jul;224(1):170-7. doi: 10.1016/j.expneurol.2010.03.007. Epub 2010 Mar 15.

14.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI.

Clin Cancer Res. 2007 Mar 15;13(6):1775-82.

15.

Experience induces structural and biochemical changes in the adult primate brain.

Kozorovitskiy Y, Gross CG, Kopil C, Battaglia L, McBreen M, Stranahan AM, Gould E.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17478-82. Epub 2005 Nov 18.

Supplemental Content

Support Center